Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allogeneic CD7-targeted CAR-T Cell Injection in the Treatment of Type 1 Diabetes

NCT07142161 is registered in ClinicalTrials.gov with Nanjing Bioheng Biotech Co., Ltd. as lead sponsor.

NCT NCT07142161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07142161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allogeneic CD7-targeted CAR-T Cell Injection in the Treatment of Type 1 Diabetes
Lead sponsor
Nanjing Bioheng Biotech Co., Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 20, 2025
Completion date
December 25, 2026
Enrollment
3 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes